/
EDIT
$2.81-$0.03 (-1.06%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$436.2M
154M shares
52-week range
$1.66 – $4.54
40% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-57.19
Editas Medicine, Inc. Common Stock
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
www.editasmedicine.com- Employees
- 87
- IPO / List date
- Feb 3, 2016
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds EDIT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 3,972,160 | $9.8M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded EDIT yet.
